Study Group: QT Interval Prolongation Experts (US)(?)

Richard Anthony, PhD, is the Chief Executive Officer at Catalyst Pharma Group, Inc., California, a contract research organization providing clinical development, regulatory and licensing representative services for pharmaceutical and biotechnology companies. He also serves as the Board Member of Janus...

Eric Gruff, PhD, MBA, BS, is the Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 16 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals,...

Leo Pavliv, RPh, MBA, is Vice President Operations at Cumberland Pharmaceuticals in Tennessee. His job responsibilities include directing overall drug development activities for numerous products, regulatory affairs, product development, clinical and non-clinical development, manufacturing, and quality...

Evan Siegel, MPhil, PhD, is the President and Chief Executive Officer at the Ground Zero Pharmaceuticals, Inc., a regulatory affairs and product development consulting firm in California. He provides services in the strategic, regulatory, preclinical, clinical CMC and compliance areas for firms developing...

Bernard Chaitman, MD, is a Professor of Internal Medicine and Director of Cardiovascular Research at St. Louis University School of Medicine, Missouri. He is also the Director of Core ECG Laboratory. Dr. Chaitman has research interests in anti-anginal drug therapies including Ranolazine, Nicorandil,...

Rami Kaminski, MD, is Director and Founder of the Institute for Integrative Psychiatry in New York, a not-for-profit organization aimed at evaluating current psychiatric services and how they integrate with medicine, such as the mutual effects between medical and psychiatric conditions. Prior to that,...